Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a clinical stage bio-pharmaceutical company with a first-in-class monoclonal antibody, bertilimumab, for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE